Anxiety, patient activation, and quality of life among stroke survivors prescribed smartwatches for atrial fibrillation monitoring

• Published in: Cardiovascular digital health journal Vol. 4; no. 4; pp. 118 - 125
• Main Authors: Paul, Tenes J., Tran, Khanh-Van, Mehawej, Jordy, Lessard, Darleen, Ding, Eric, Filippaios, Andreas, Howard-Wilson, Sakeina, Otabil, Edith Mensah, Noorishirazi, Kamran, Naeem, Syed, Hamel, Alex, Han, Dong, Chon, Ki H., Barton, Bruce, Saczynski, Jane, McManus, David
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2023; Elsevier
• Subjects: Atrial fibrillation; Elderly; Original; Smartwatches; Stroke; Wearables; Wearables; Stroke; Elderly; Atrial fibrillation; Smartwatches
• ISSN: 2666-6936; 2666-6936
• DOI: 10.1016/j.cvdhj.2023.04.002

The detection of atrial fibrillation (AF) in stroke survivors is critical to decreasing the risk of recurrent stroke. Smartwatches have emerged as a convenient and accurate means of AF diagnosis; however, the impact on critical patient-reported outcomes, including anxiety, engagement, and quality of life, remains ill defined. To examine the association between smartwatch prescription for AF detection and the patient-reported outcomes of anxiety, patient activation, and self-reported health. We used data from the Pulsewatch trial, a 2-phase randomized controlled trial that included participants aged 50 years or older with a history of ischemic stroke. Participants were randomized to use either a proprietary smartphone-smartwatch app for 30 days of AF monitoring or no cardiac rhythm monitoring. Validated surveys were deployed before and after the 30-day study period to assess anxiety, patient activation, and self-rated physical and mental health. Logistic regression and generalized estimation equations were used to examine the association between smartwatch prescription for AF monitoring and changes in the patient-reported outcomes. A total of 110 participants (mean age 64 years, 41% female, 91% non-Hispanic White) were studied. Seventy percent of intervention participants were novice smartwatch users, as opposed to 84% of controls, and there was no significant difference in baseline rates of anxiety, activation, or self-rated health between the 2 groups. The incidence of new AF among smartwatch users was 6%. Participants who were prescribed smartwatches did not have a statistically significant change in anxiety, activation, or self-reported health as compared to those who were not prescribed smartwatches. The results held even after removing participants who received an AF alert on the watch. The prescription of smartwatches to stroke survivors for AF monitoring does not adversely affect key patient-reported outcomes. Further research is needed to better inform the successful deployment of smartwatches in clinical practice.